2024-07-09 19:17:18
Samsung Bio’s first independent booth
Emphasizes the competitiveness of the world’s largest and highest quality CDMO
Strengthening the market strategy for the consignment development of ‘next-generation anticancer drugs’ ADC
‘Bioplus Interpex Korea’ held at COEX on the 10th
An industrial exchange venue with the participation of over 250 domestic and international companies
Samsung BioLogics announced on the 9th that it will participate in the pharmaceutical and bio industry business event ‘BioPlus Interphex Korea 2024’ to be held at COEX in Samseong-dong, Gangnam-gu, Seoul from the 10th to the 12th.
This event is held as a venue for sharing domestic and international pharmaceutical and bio industry supply chains and discussing partnerships through business networking. It is hosted by the Korea Bio Association and RX Korea.
This year, the theme is ‘The World’s Most Tangible Bio-healthcare Convention’. Approximately 250 companies are expected to participate and over 10,000 people are expected to visit.
Samsung BioLogics has set up a standalone booth in the exhibition hall for the first time this year. The purpose is to publicize its strengthened global contract development and manufacturing (CDMO) capabilities, including its continuously expanding contract manufacturing (CMO) capabilities and new contract development (CDO) technology platforms. The booth will be decorated with LED screens and wall graphics. Through these, it plans to introduce the world’s largest biopharmaceutical production capacity (approximately 1,324,000 liters) expected to be secured by 2032, the differentiated competitiveness of its contract development services, and its expanded portfolio including antibodies, drug conjugates (ADCs), and messenger ribonucleic acid (mRNA). In particular, Samsung BioLogics has fully entered the competition for ADC contract development and manufacturing ahead of the completion and operation of a dedicated production facility for ADC drugs, which are attracting attention as next-generation anticancer drugs, within the year. It is actively seeking to secure customers.
Also, Lim Heon-chang, Group Leader of Samsung BioLogics Formulation Development Group, will participate as a speaker in the conference session at this event. He will introduce Samsung BioLogics’ new drug candidate discovery platform, DevelopPick, and CDO capabilities under the theme of ‘Development Feasibility Assessment Tool-based Successful Candidate Selection and Successful New Drug Development’. For booth visitors, they will provide digital brochures via QR codes, eco-friendly souvenirs, and jute bags (hemp bags) to inform them of their commitment to ESG practices.
Samsung BioLogics is also carrying out online and offline sponsorship activities as part of its efforts to raise brand awareness. It will install banners throughout its booth and actively introduce Samsung BioLogics’ vision and service competitiveness through digital banner exposure on its website and newsletter.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-07-09 19:17:18